参芎葡萄糖注射液结合常规疗法治疗乙型肝炎肝纤维化临床观察  

Clinical observation of "Shenxiong Injection" and routine modality in treating hepatic fibrosis following hepatitis B

作　　者：刘绍龙[1] 蒋烽炼[1] 韩方方[1] 于媛[1] 卜高峰 

机构地区：[1]江苏省徐州市传染病医院中西医结合科,江苏徐州221004

出　　处：《上海中医药杂志》2012年第11期39-40,共2页Shanghai Journal of Traditional Chinese Medicine

摘　　要：目的观察参芎葡萄糖注射液结合常规疗法治疗乙型肝炎肝纤维化的临床疗效。方法将86例乙型肝炎肝纤维化患者随机分为两组;对照组43例采用常规保肝治疗,治疗组43例在保肝治疗基础上加用参芎葡萄糖注射液静脉滴注,共3个疗程。结果治疗组总有效率为88.4%,对照组为65.1%(P<0.01)。治疗后,两组肝功能指标ALT、AST、TBIL均有所降低(P<0.01),治疗组ALB升高(P<0.05),且两组诸指标比较有显著性差异(P<0.05,P<0.01);两组肝纤维化指标HA、PC-Ⅲ、Ⅳ-C、LN均有所降低(P<0.05,P<0.01),且治疗组低于对照组(P<0.01)。结论参芎葡萄糖注射液能改善乙型肝炎肝纤维化患者肝功能和肝纤维化。Objective To observe the clinical efficacy of ＂Shenxiong Injection＂ and routine modality in the treatment of hepatic fibrosis following hepatitis B.Methods Eight-six subjects were randomized into two groups： control group in which 43 cases were treated by routine modality and treatment group in which 43 cases were treated with ＂Shenxiong Injection＂ and routine modality for three courses.Results The overall effective rate was 88.4% in the treatment group and 65.1% in the control group,with a striking difference between the two groups（P0.01）.After treatment,the contents of ALT,AST and TBIL were decreased in both groups（P0.01）,and the content of ALB was increased in the treatment group（P0.05）;there were great differences in the contents of ALT,AST,TBIL and ALB between the two groups（P0.05,P0.01）.After treatment,the contents of HA,PC-Ⅲ,Ⅳ-C and LN were decreased in both groups（P0.05,P0.01）,with lower contents in the treatment group than in the control group（P0.01）.Conclusion ＂Shenxiong Injection＂ helps improve liver function and fight hepatic fibrosis following hepatitis B.

关 键 词：乙型肝炎 肝纤维化 参芎葡萄糖注射液 

分 类 号：R512.62[医药卫生—内科学]